The average of price targets set by Wall Street analysts indicates a potential upside of 65.5% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Enovis NYSE: ENOV reported a solid start to 2026, with management pointing to share gains in its reconstructive surgery business, stable growth in prevention and recovery, and continued investment in new products including ARVIS and Nebula.
Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Mason Hawkins Southeastern Asset Management | 44,258 | $1.81M | $953,317.32 | -$852,335.57 | -47.2% |
Bridgewater Associates LP Bridgewater Associates LP | 51,224 | $1.17M | $1.1M | -$61,981.04 | -5.32% |
Andrew Kirchner ELEVATION WEALTH PARTNERS, LLC | 7 | $187 | $150.78 | -$36.22 | -19.37% |
Alexandra Stickelman Root Financial Partners, LLC | 192 | $4,751.21 | $4,135.68 | -$615.53 | -12.95% |
Christopher C. Powers Farther Finance Advisors, LLC | 1,101 | $38,285.91 | $23,715.54 | -$14,570.37 | -38.06% |
| Machinery Industry | Industrials Sector | Damien McDonald CEO | NYSE Exchange | 194014502 CUSIP |
| US Country | 7,367 Employees | - Last Dividend | 5 Apr 2022 Last Split | - IPO Date |
Enovis Corporation, a notable entity in the medical technology landscape, operates on a global scale. It specializes in the development, manufacture, and distribution of a varied portfolio of medical device products. These products are designed to cater to the needs of orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and a broad spectrum of other healthcare professionals. The primary focus of the company is to provide solutions for patients suffering from musculoskeletal conditions that arise due to degenerative diseases, deformities, traumatic events, and sports-related injuries. Initially known as Colfax Corporation, Enovis Corporation has rooted its headquarters in Wilmington, Delaware, illustrating a significant presence in the medical technology domain.
Enovis Corporation delivers an extensive array of products and services across the medical technology field:
Moreover, Enovis Corporation markets its cutting-edge products through a combination of independent distributors, including healthcare professionals, consumer retail stores, and pharmacies, and directly to consumers under the notable DJO brand. This strategic approach allows the company to span a wide market, reaching various healthcare providers and patients efficiently.